A
High ConfidenceREDUCE-IT: Cardiovascular Risk Reduction with Icosapent Ethyl
Bhatt DL, et al • N Engl J Med
Key Finding
Icosapent ethyl significantly reduces cardiovascular events in high-risk patients.
Original title: “Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia”
Plain English Summary
Major trial showing EPA supplementation reduces cardiovascular events in patients with elevated triglycerides.
Paradigm Relevance
How this study applies to different clinical perspectives:
Standard Medical
RelevantConventional clinical guidelines used by most doctors
Research Consensus
RelevantCurrent scientific understanding, often ahead of guidelines
Metabolic Optimization
RelevantProactive targets for optimal health, not just disease absence
Study Details
- Type
- Landmark Study
Related Biomarkers
TRIGLYCERIDES